Avidity Biosciences, Inc. is a biotechnology company focused on developing a new class of targeted RNA therapeutics aimed at profoundly improving people's lives. They are pioneering the use of Antibody Oligonucleotide Conjugates (AOC ™) to address the root causes of diseases, beginning with their muscle disease franchise, which includes conditions like myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). By combining the specificity of monoclonal antibodies with the precision of oligonucleotides, Avidity's AOC platform delivers therapies to previously inaccessible tissues and more effectively targets the genetic drivers of diseases. With an agile and diverse team, they aim to expand their pipeline to treat a wide range of therapeutic areas.